Neoadjuvant paclitaxel (P), carboplatin (Ca) and gemcitabine (G) in patients with locally advanced transitional cell carcinoma (TCC) of the bladder: A final report.

被引：0
|
作者：
Smith, D. C.
Mackler, N. J.
Hussain, M. H.
Dunn, R.
Montie, J. E.
Wood, D.
Lee, C. T.
Petrylak, D.
Quinn, D.
Vaishampayan, U.
机构：
[1] Univ Michigan, Ann Arbor, MI 48109 USA
[2] Columbia Presbyterian Med Ctr, New York, NY USA
[3] Univ So Calif, Los Angeles, CA USA
[4] Wayne State Univ, Detroit, MI USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2006年 / 24卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：226S / 226S
页数：1
相关论文
共 50 条
  • [1] Paclitaxel, carboplatin and gemcitabine (PCG) as neoadjuvant therapy in patients with locally advanced transitional cell carcinoma (TCC) of the bladder.
    Smith, DC
    Bhandari, M
    Hussain, M
    Montie, JE
    Wood, DP
    Lee, CT
    Petrylak, DP
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 392S - 392S
  • [2] Phase II Trial of Paclitaxel, Carboplatin and Gemcitabine in Patients With Locally Advanced Carcinoma of the Bladder
    Smith, David C.
    Mackler, Niklas J.
    Dunn, Rodney L.
    Hussain, Maha
    Wood, David
    Lee, Cheryl T.
    Sanda, Martin
    Vaishampayan, Ulka
    Petrylak, Daniel P.
    Quinn, David I.
    Beekman, Kathleen
    Montie, James E.
    JOURNAL OF UROLOGY, 2008, 180 (06): : 2384 - 2388
  • [3] A Phase II Trial of Neoadjuvant nab-paclitaxel, Carboplatin, and Gemcitabine (ACaG) in Patients With Locally Advanced Carcinoma of the Bladder
    Grivas, Petros D.
    Hussain, Maha
    Hafez, Khaled
    Daignault-Newton, Stephanie
    Wood, David
    Lee, Cheryl T.
    Weizer, Alon
    Montie, James E.
    Hollenbeck, Brent
    Montgomery, Jeffrey S.
    Alva, Ajjai
    Smith, David C.
    UROLOGY, 2013, 82 (01) : 111 - 117
  • [4] Phase II Trial of Paclitaxel, Carboplatin and Gemcitabine in Patients With Locally Advanced Carcinoma of the Bladder COMMENT
    Tagawa, Scott T.
    JOURNAL OF UROLOGY, 2008, 180 (06): : 2388 - 2388
  • [5] Phase I trial of paclitaxel, cisplatin, and gemcitabine (TCG) in patients (p) with advanced transitional cell carcinoma (TCC) of the urothelium
    Bellmunt, J
    Baselga, J
    SEMINARS IN ONCOLOGY, 1999, 26 (01) : 140 - 140
  • [6] CARBOPLATIN AND GEMCITABINE IN ELDERLY AND/OR FRAIL PATIENTS (PTS) WITH ADVANCED TRANSITIONAL CELL CARCINOMA (TCC): A PHASE II STUDY
    Baitar, A.
    De Vos, M.
    Vandebroek, A.
    Schrijvers, D.
    ANNALS OF ONCOLOGY, 2010, 21 : 281 - 281
  • [7] Phase II study of Taxol (paclitaxel) and Carboplatin in patients with advanced transitional-cell carcinoma of the urothelium (TCC)
    Mottet, N
    Prapotnich, D
    Beuzeboc, P
    Di Palma, M
    Bui, N
    Eymard, JC
    Mercat, A
    Garet, F
    Droz, JP
    ANNALS OF ONCOLOGY, 1998, 9 : 59 - 59
  • [8] Gemcitabine and paclitaxel regimen for patients with advanced transitional cell carcinoma
    Takahashi, T
    Higashi, S
    Nishiyama, H
    Itoh, N
    Yamamoto, S
    Kamoto, T
    Ogawa, O
    JOURNAL OF UROLOGY, 2005, 173 (04): : 359 - 360
  • [9] Intra vesical gemcitabine (G) single agent as adjuvant chemotherapy in superficial transitional cell carcinoma (TCC) of the bladder: Final results
    Bounedjar, A.
    Ferhat, R.
    Smaili, F.
    Bouzid, K.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [10] Gemcitabine and paclitaxel in previously treated patients with advanced transitional cell carcinoma
    Marini, L
    Sternberg, C
    Sella, A
    Calabro, F
    Van Rijn, A
    EUROPEAN JOURNAL OF CANCER, 1999, 35 : S348 - S349
12345